(Q38084617)

28 August 2017

title

Promising new molecular targeted therapies in head and neck cancer (English)

1 reference

28 August 2017

Kelly Dorsey

1

1 reference

28 August 2017

Mark Agulnik

series ordinal

2

1 reference

28 August 2017

publication date

1 March 2013

1 reference

28 August 2017

1 reference

28 August 2017

volume

73

1 reference

28 August 2017

issue

4

1 reference

28 August 2017

page(s)

315-325

1 reference

https://scigraph.springernature.com/pub.10.1007/s40265-013-0025-3

28 August 2017

exact match

0 references

cites work

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

The changing face of head and neck cancer in the 21st century: the impact of HPV on the epidemiology and pathology of oral cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

The p53 network in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

Human papillomavirus and survival of patients with oropharyngeal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

End points for new agents in induction chemotherapy for locally advanced head and neck cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

The expanding role of systemic therapy in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

The ErbB receptors and their role in cancer progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

The ErbB receptor tyrosine family as signal integrators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

Ligand-induced, receptor-mediated dimerization and activation of EGF receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

Untangling the ErbB signalling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

The roles of JNK1 and Stat3 in the response of head and neck cancer cell lines to combined treatment with all-trans-retinoic acid and 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

The role of ubiquitylation in signaling by growth factors: implications to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

Epidermal growth factor receptor dependence in human tumors: more than just expression?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

EGFR and cancer prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

Platinum-based chemotherapy plus cetuximab in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

Biology of interactions: antiepidermal growth factor receptor agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

What Is the Evidence That Tumors Are Angiogenesis Dependent?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

Computational identification of inhibitors of protein-protein interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

Potential autocrine function of vascular endothelial growth factor in head and neck cancer via vascular endothelial growth factor receptor-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

The IGF-1 receptor and its contributions to metastatic tumor growth-novel approaches to the inhibition of IGF-1R function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

Structure and function of the type 1 insulin-like growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

Insulin-like growth factor receptor as a therapeutic target in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

Insulin-like growth factors and neoplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

Phase II study of sunitinib malate in head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Base

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0025-3

Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

21 January 2018

1 reference

12 December 2020

Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association.

1 reference

12 December 2020

Role of insulin-like growth factor 1 receptor signalling in cancer

1 reference

12 December 2020

Distinct mechanisms mediate the initial and sustained phases of cell migration in epidermal growth factor receptor-overexpressing cells

1 reference

12 December 2020

EGFR targeting of solid tumors

1 reference

12 December 2020

Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies

1 reference

12 December 2020

Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis

1 reference

12 December 2020

Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm

1 reference

12 December 2020

Molecular design and clinical development of VEGFR kinase inhibitors

1 reference

12 December 2020

Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study

1 reference

12 December 2020

10.1007/S40265-013-0025-3

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

1042318507

0 references

1 reference